Medicago Press Release: Q&A: How real is the threat of a global pandemic involving H5N1 or a related virus?

Wed Jul 18, 2012 8:34am EDT
Andy Sheldon is the CEO of Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) (PINK:MDCGF).

His firm has completed a Phase I and a Phase II clinical trial of an H5 pandemic flu VLP vaccine candidate and he shares with BioMedReports an overview of progress on several fronts in this exclusive interview. Read More

How real is the threat of a global pandemic involving H5N1 or a related virus?
Very real. Two studies published this year in Nature and Science highlight the pandemic potential of viruses possessing an H5 HA, and it appears to be much easier than previously thought. The continued evolution of H5N1 viruses reinforces the need to prepare and update candidate vaccines to H5 viruses and, together, the two papers demonstrate that the natural evolution of an H5N1 virus to a transmissible, highly pathogenic human pandemic virus is possible.
-snip-
[Click on title above for link]

The full interview with Andy Sheldon is the CEO of Medicago Inc is available at:

http://www.biomedreports.com/20120718100206/qaa-andy-sheldon-the-ceo-of-medicago-inc.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com